Institutional Equity Research for Undercovered Public Companies
Alliance Equity Research publishes independent and company-sponsored research on undercovered, emerging, and high-potential public companies globally.
Search AER-covered companies and Insights, or explore listed companies across supported global markets.
Latest Research
Recent initiation reports, research updates and company commentary from Alliance Equity Research.
ASML Holding N.V.
ASML
A Near-Monopoly Lithography Franchise Powering Global Semiconductor Supply Chain with EUV Dominance and High-NA Optionality
Initiation coverage examining EUV leadership, High-NA optionality, DUV economics, installed-base services, competitive moat, semiconductor demand drivers, valuation summary, and key risks.
Dexcom, Inc.
DXCM
Dominant CGM Franchise Leveraging Technology, Coverage Expansion, and Consumer Tailwinds to Sustain Multi-Year Growth
Initiation coverage examining CGM market leadership, product strategy, reimbursement expansion, recurring sensor economics, international growth, valuation summary, and key risks.
Insights
Commentary, market context, and research process notes from Alliance Equity Research.
Healthcare & BiotechnologyJaypirca Moves Into First-Line CLL, Expanding Lilly’s Oncology Opportunity in a Crowded Market
FDA approval brings Lilly’s noncovalent BTK inhibitor into initial treatment for eligible patients with chronic lymphocytic leukemia. The commercial opportunity now extends earlier in the disease course, while competing targeted therapies, treatment duration and tolerability will determine how much of that opportunity becomes revenue.
EnergyFlowco’s $113 Million Deal Expands Its Role in Keeping Older Wells Productive
Flowco’s acquisition of Lifting Solutions adds continuous rod and progressing cavity pumps to its artificial lift portfolio. The purchase extends its Canadian and international reach, with returns dependent on equipment performance, cross-selling and cash generation as the group absorbs a second acquisition this year.
Technology & SemiconductorsMicron’s Customers Are Helping Fund Its Next Expansion as Memory Demand Surges
Customer deposits exceeded Micron’s quarterly net capital expenditure as revenue and operating cash flow reached new highs. Combined with longer-term purchase agreements, that funding gives Micron greater capacity to expand supply, while shifting the investment debate toward contract profitability and returns on new factories.
Mining & Critical MineralsNth Cycle’s $1 Billion Glencore Deal Addresses Demand, but Leaves Its Funding Test Unfinished
Glencore’s proposed feedstock and offtake arrangements strengthen Nth Cycle’s commercial case ahead of its planned SPAC merger. Converting that demand into shareholder value still requires definitive contracts, construction funding and profitable refinery operations.
Biotechnology & HealthcareSurrozen’s FDA Clearance Unlocks $95 Million and a Clinical Test
SZN-8141 can now enter the clinic just as Merck has validated Wnt activation in diabetic macular edema. A pre-committed $95.1 million financing gives Surrozen capital to test whether combining Wnt activation with VEGF inhibition can improve on either mechanism alone.
Mining & Critical Minerals5E Bought a $147 Million Revenue Boron Business for Roughly $36 Million, but the Discount Comes With Real Risk
5E Advanced Materials has acquired Searles Valley Minerals through bankruptcy, turning a pre-revenue developer into an operating U.S. borates producer. The purchase price looks exceptionally low relative to the acquired business's historical sales, but 14.5% PIK seller financing, a short-term bridge loan, meaningful equity dilution and Searles Valley's recent losses show why the assets were available so cheaply.
Technology & SemiconductorsOnsemi Cut $1.3 Billion From Its Synaptics Deal and Made Both Stocks More Valuable
Onsemi’s revised Synaptics acquisition replaces a roughly $7 billion all-stock transaction with a $5.7 billion cash deal after an unsolicited competing proposal. The unusual result is better economics for the buyer, greater certainty for the seller and a positive market reaction for both stocks.
Biotechnology & HealthcareFoghorn Lost Its Lilly Partnership, but the 40% Workforce Cut Changes the Valuation Math
Foghorn Therapeutics has discontinued FHD-909 and effectively ended a collaboration that brought in $380 million of upfront cash and equity from Lilly. The clinical failure removes its most advanced partnered asset, but a 40% workforce reduction extends cash runway into the second half of 2029 and leaves the company with $167.6 million of June cash and securities against a market value of roughly $200 million.
Explore Coverage
AER-covered companies combine public-company information with our proprietary research, updates, and commentary.
Find AER-Covered Companies
Explore AER-covered companies by sector, region, and market capitalization.
Research Built Around the Model
Alliance Equity Research develops written company analysis and detailed financial models together. The model is used to test operating assumptions, financial outcomes, scenarios, and valuation frameworks.
- Fundamental company analysis
- Integrated financial modeling
- Scenario-based valuation framework
- Ongoing coverage after initiation
Operating Drivers
RevenuePricingVolumeKPIsFinancial Forecast
Illustrative forecast structure, without financial values Metric FY1 FY2 FY3 FY4 Revenue Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder EBITDA Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder FCF Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder Scenarios & Sensitivities
BaseUpsideDownsideValuation
DCF · Trading Multiples
Published Research
Is Your Company Undercovered?
Alliance Equity Research works with listed, recently listed, and companies preparing to list. Coverage may include initiation research, detailed financial modeling, and ongoing research updates.
- Initiation Research
- Financial Model
- Ongoing Updates
Investor Discovery
- AER Website
- AlphaSense
- FactSet
- Distribution Partners
Stay Current with AER
Choose the research and Insights updates you want to receive.